Overview

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.

Phase:

Phase 3

Details

Lead Sponsor:

Purdue Pharma LP

Treatments:

Hydrocodone